4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $38.56.
Several analysts have commented on the stock. Royal Bank of Canada decreased their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Chardan Capital reiterated a “buy” rating and issued a $39.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Saturday, January 18th. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $40.00 to $15.00 in a research note on Monday, January 13th. Finally, Bank of America decreased their target price on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th.
Check Out Our Latest Analysis on 4D Molecular Therapeutics
Hedge Funds Weigh In On 4D Molecular Therapeutics
4D Molecular Therapeutics Trading Down 1.5 %
Shares of NASDAQ FDMT opened at $4.65 on Friday. 4D Molecular Therapeutics has a 12 month low of $4.43 and a 12 month high of $36.25. The company has a 50 day simple moving average of $6.16 and a two-hundred day simple moving average of $10.51. The stock has a market cap of $214.97 million, a price-to-earnings ratio of -1.63 and a beta of 2.81.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
See Also
- Five stocks we like better than 4D Molecular Therapeutics
- Quiet Period Expirations Explained
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- The How and Why of Investing in Gold Stocks
- What Does the Future Hold for Eli Lilly?
- 10 Best Airline Stocks to Buy
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.